157 related articles for article (PubMed ID: 18620901)
1. Is there a role for the Fas-/Fas-Ligand pathway in chemoresistance of human squamous cell carcinomas of the head and neck (SCCHN)?
Sproll KC; Balló H; Hoffmann TK; Scheckenbach K; Koldovsky U; Balz V; Hafner D; Ramp U; Bier H
Oral Oncol; 2009 Jan; 45(1):69-84. PubMed ID: 18620901
[TBL] [Abstract][Full Text] [Related]
2. FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis.
Wieckowski E; Atarashi Y; Stanson J; Sato TA; Whiteside TL
J Cell Biochem; 2007 Jan; 100(1):16-28. PubMed ID: 16888780
[TBL] [Abstract][Full Text] [Related]
3. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes.
Gastman BR; Atarshi Y; Reichert TE; Saito T; Balkir L; Rabinowich H; Whiteside TL
Cancer Res; 1999 Oct; 59(20):5356-64. PubMed ID: 10537320
[TBL] [Abstract][Full Text] [Related]
4. Induction of Fas expression and augmentation of Fas/Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells.
Sun SY; Yue P; Hong WK; Lotan R
Cancer Res; 2000 Nov; 60(22):6537-43. PubMed ID: 11103825
[TBL] [Abstract][Full Text] [Related]
5. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
6. B7.1 on human carcinomas: costimulation of T cells and enhanced tumor-induced T-cell death.
Lang S; Atarashi Y; Nishioka Y; Stanson J; Meidenbauer N; Whiteside TL
Cell Immunol; 2000 May; 201(2):132-43. PubMed ID: 10831322
[TBL] [Abstract][Full Text] [Related]
7. Retention of the arginine allele in codon 72 of the p53 gene correlates with poor apoptosis in head and neck cancer.
Schneider-Stock R; Mawrin C; Motsch C; Boltze C; Peters B; Hartig R; Buhtz P; Giers A; Rohrbeck A; Freigang B; Roessner A
Am J Pathol; 2004 Apr; 164(4):1233-41. PubMed ID: 15039212
[TBL] [Abstract][Full Text] [Related]
8. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
9. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
10. Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis.
Xi S; Dyer KF; Kimak M; Zhang Q; Gooding WE; Chaillet JR; Chai RL; Ferrell RE; Zamboni B; Hunt J; Grandis JR
J Natl Cancer Inst; 2006 Feb; 98(3):181-9. PubMed ID: 16449678
[TBL] [Abstract][Full Text] [Related]
11. Up-regulation of Fas (APO-1/CD95) ligand and down-regulation of Fas expression in human esophageal cancer.
Gratas C; Tohma Y; Barnas C; Taniere P; Hainaut P; Ohgaki H
Cancer Res; 1998 May; 58(10):2057-62. PubMed ID: 9605741
[TBL] [Abstract][Full Text] [Related]
12. FasL gene therapy: a new therapeutic modality for head and neck cancer.
ElOjeimy S; McKillop JC; El-Zawahry AM; Holman DH; Liu X; Schwartz DA; Day TA; Dong JY; Norris JS
Cancer Gene Ther; 2006 Aug; 13(8):739-45. PubMed ID: 16543918
[TBL] [Abstract][Full Text] [Related]
13. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
14. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced apoptosis is associated with enhanced Fas (Apo-1/CD95) ligand expression but occurs independently of Fas (Apo-1/CD95) signaling in human T-acute lymphatic leukemia cells.
Villunger A; Egle A; Kos M; Hartmann BL; Geley S; Kofler R; Greil R
Cancer Res; 1997 Aug; 57(16):3331-4. PubMed ID: 9269989
[TBL] [Abstract][Full Text] [Related]
16. Surface membrane-expressed CD40 is present on tumor cells from squamous cell cancer of the head and neck in vitro and in vivo and regulates cell growth in tumor cell lines.
Posner MR; Cavacini LA; Upton MP; Tillman KC; Gornstein ER; Norris CM
Clin Cancer Res; 1999 Aug; 5(8):2261-70. PubMed ID: 10473114
[TBL] [Abstract][Full Text] [Related]
17. Is FAS/Fas ligand system involved in equine corpus luteum functional regression?
Galvao AM; Ramilo DW; Skarzynski DJ; Lukasik K; Tramontano A; Mollo A; Mateus LM; Ferreira-Dias GM
Biol Reprod; 2010 Dec; 83(6):901-8. PubMed ID: 20720169
[TBL] [Abstract][Full Text] [Related]
18. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
19. Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis.
Andrews GA; Xi S; Pomerantz RG; Lin CJ; Gooding WE; Wentzel AL; Wu L; Sidransky D; Grandis JR
Head Neck; 2004 Oct; 26(10):870-7. PubMed ID: 15390206
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of Fas and FasL pro-apoptotic proteins in basal cell and squamous cell carcinomas.
Wang XY; Zhang R; Lian S
Clin Exp Dermatol; 2011 Jan; 36(1):69-76. PubMed ID: 20497185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
